Trials / Completed
CompletedNCT00002171
A Study of Viracept in HIV-Positive Women
A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Agouron Pharmaceuticals · Industry
- Sex
- Female
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nelfinavir mesylate |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002171. Inclusion in this directory is not an endorsement.